HUTCHMED
-
HUTCHMED to Unveil 2025 Full-Year Financial Results
HUTCHMED is set to release its 2025 financial results, an event of keen interest for investors. The biopharmaceutical company’s performance in oncology and immunology drug development and commercialization will be closely examined. Investors will focus on revenue growth from marketed drugs and the progress of its late-stage pipeline, alongside R&D investments and clinical trial updates. The report will also cover strategic outlook, manufacturing, and regulatory navigation, offering insights into the company’s trajectory and its ability to deliver innovative medicines.
-
HUTCHMED Appoints Acting CEO
HUTCHMED (HCM) CEO Dr. Weiguo Su is taking a leave of absence for health reasons. CFO Johnny Cheng has been appointed Acting CEO, retaining his CFO responsibilities. The Board assures that ongoing research, development, and commercial activities will remain on track. Dr. Su expressed confidence in the team’s ability to execute the company’s strategy. Cheng acknowledged Dr. Su’s 20 years of leadership and contributions to HUTCHMED.
